TNFRSF17 and plasma cell myeloma: Clinical outcomes of patients treated with an anti-BCMA ADC, AMG-224, correlated with sBCMA levels (31), and ongoing phase III DREAM-5 clinical trials for belantamab mafodotin include cotreatment with a γ-secretase inhibitor to reduce sBCMA levels and increase membrane BCMA expression on multiple myeloma cells (NCT04126200).